RxDoctor Payments Data

Andrew Wong, MD

Neurology · San Antonio, TXNPI 1407172521

Payments from drug & device makers

$9,715in general payments, 2019–2025

Across 470 payments — averaging $20.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$901
  • EMD Serono, Inc.$479
  • Biogen$429
  • Sanofi$414
  • AstraZeneca$385
  • AbbVie$377
  • plus $7K from 52 others

What the payments were for

  • Food & beverage$9,48798%
  • Education$2282%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.43$901
EMD Serono, Inc.28$479
Biogen18$429
Sanofi20$414
AstraZeneca(2 entities)19$385
AbbVie(2 entities)22$377
Takeda Pharmaceuticals U.S.A., Inc.13$365
Teva Pharmaceuticals USA, Inc.32$359
TG Therapeutics, Inc.22$357
Argenx US, Inc.14$341
Novartis16$336
Acadia Pharmaceuticals Inc17$326
Genentech USA, Inc.14$323
Amgen(2 entities)16$319
CSL Behring13$304
Catalyst Pharmaceuticals, Inc.10$257
Octapharma USA, Inc.11$233
Pfizer20$200
SK Life Science, Inc.9$189
Tanabe Pharma America, Inc.7$189
Grifols USA, LLC7$178
Livanova USA, Inc.8$165
Royal Biologics, Inc.1$153
Johnson & Johnson3$148
Akcea Therapeutics, Inc.5$147
Eisai Inc.6$120
Bristol Myers Squibb4$114
Xeris Pharmaceuticals, Inc.5$110
Jazz Pharmaceuticals Inc.4$107
Mallinckrodt Hospital Products Inc.5$99
Alnylam Pharmaceuticals Inc.4$86
Lundbeck LLC3$82
Neurelis, Inc.2$81
GE HealthCare3$80
GRT US Holding, Inc.3$77
Amylyx Pharmaceuticals, Inc.4$77
ANI Pharmaceuticals, Inc.3$76
Biohaven Pharmaceutical Holding Company Ltd.3$72
Lilly USA, LLC4$72
Avanir Pharmaceuticals, Inc.3$58
Amneal Pharmaceuticals LLC2$52
MDD US Operations, LLC3$52
Supernus Pharmaceuticals, Inc.3$49
Axsome Therapeutics, Inc.2$48
Kedrion Biopharma, Inc.2$40
Sumitomo Pharma America, Inc.2$37
Merz Pharmaceuticals, LLC1$28
Janssen Scientific Affairs, LLC1$27
Hospira, Inc.1$26
Medtronic1$25
Biohaven Pharmaceuticals, Inc.1$23
Shire North American Group Inc1$20
Ultragenyx Pharmaceutical Inc.1$20
Azurity Pharmaceuticals, Inc.1$20
Tactile Systems Technology Inc1$19
Almatica Pharma LLC1$19
Electromed, Inc.1$14
Strongbridge US Inc.1$14

How this compares

$9,715 in reported general payments places this provider in the 65th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$2,663,818
Medicare patients
179
Services billed
56,630

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OctagamImmun Globg(Igg)/Malt/Iga Ov50140$1,630,102
GammakedImmune Globul G/Gly/Iga Avg 4670$1,482,225
PrivigenImmun Glob G(Igg)/Pro/Iga 0-50123$1,419,718
GammaplexImmun Glob G(Igg)/Gly/Iga 0-50102$911,954
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5050$510,607
HizentraImmun Glob G(Igg)/Pro/Iga 0-5049$509,469
CuvitruImmun Glob G(Igg)/Gly/Iga Ov5020$172,938
PanzygaImmun Glob G(Igg)-Ifas/Glycine12$137,857
Aimovig AutoinjectorErenumab-Aooe13$20,783
BriviactBrivaracetam13$19,813
QuliptaAtogepant16$19,242
GlatopaGlatiramer Acetate12$16,676
GraliseGabapentin16$15,388
Epinephrine23$6,197
Methylprednisolone Sodium SuccMethylprednisolone Sod Succ100$3,928

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringPrivigen, Hizentra$304$1,929,186172 claims
PfizerOctagam, Panzyga$200$1,767,959152 claims
Kedrion Biopharma, Inc.Gammaked$40$1,482,22570 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid, Cuvitru$365$683,54670 claims
UCB, Inc.Briviact$901$19,81313 claims
AbbVieQulipta$377$19,24216 claims
Almatica Pharma LLCGralise$19$15,38816 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil$52$4,36744 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,246 neurology providers in Texas.

Other neurology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →